Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

AARD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $21.59M (cash outflow) rose 131.9% year over year, behind the +152.1% change in trailing-twelve-month net income. Sequentially, it rose 22.7% from the prior quarter. Over 3 fiscal years it compounded at +61.9% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of -$83.24M (+44.5%) for the fiscal year ending Dec 2026, a slowdown from the +179.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.59M+22.7% QoQ
Last fiscal yearDec 2025
-$57.59M+179.7% YoY
LTMMar 2026
-$69.87M+152.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+131.9%+30.3%-101.5 pp
1 year+179.7%+44.5%-135.2 pp
3-year CAGR+61.9%+8.4%-53.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(57.59M) USD
Year-over-year change
-179.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AARD compares with its peers on the latest reported figures

  • AARD's LTM Mar 2026 net income of $69.87M is the 7th largest of the 11 companies compared; the peer median is $76.38M.
  • Its year-over-year change of +152.1% is the highest of 11, against a peer median of -15.5%.
  • Over three fiscal years its annual growth of +61.9% compares with a peer median of -4.6%.
AARD Competitors Peer median
Net Income for AARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$133.22M -9.9%+14.2%1189.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M -216.1%+23.4%143627.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M -21.5%-9.9%36891.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$81.74M -14.2%-13.0%589.8%
ZURAZura Bio LimitedLTM Mar 2026$77.43M +24.7%+35.9%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$69.87M +152.1%+61.9%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M -35.7%-12.4%89.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M -16.9%+0.6%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.72M +84.6%+27.3%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$6.38M -84.0%-59.6%9.0%
Peer median (excluding AARD) $76.38M-15.5%-4.6%589.8%

Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Depreciation & Amortization110K97K16K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation412K313K439K3.95M
Change in Working Capital(1.31M)(81K)1.57M356K
Accounts Receivables0000
Inventory0000
Accounts Payables31K776K798K239K
Other Working Capital(1.34M)(857K)775K117K
Other Non-Cash Items3.81M1.06M473K421K
Operating Cash Flow(10.54M)(5.82M)(18.09M)(54.17M)
Capital Expenditures00(109K)(95K)
Acquisitions (Net)0000
Purchases of Investments00(11.89M)(129.6M)
Sales of Investments00080.03M
Other Investing Activities(1M)000
Investing Cash Flow(1M)0(12M)(49.67M)
Debt Repayment(1M)000
Common Stock Issued225K0332K89.25M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities1M0(3.34M)0
Financing Cash Flow225K081.99M89.25M
Effect of Forex Changes0000
Net Change in Cash(11.32M)(5.82M)51.91M(14.59M)
Free Cash Flow(10.54M)(5.82M)(18.2M)(54.27M)

Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Intrinsic Alpha fair value

Locked

Current Price

$3.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.